×
About 246,244 results

Open Data
https://opendata.ncats.nih.gov/covid19/

NCATS is generating a collection of datasets by screening a panel of SARS-CoV-2-related assays against all approved drugs These datasets, as well as the assay protocols used to generate them, are being made immediately available to the scientific community on this site as these screens are completed

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter study conducted in patients with AML to determine if integrated palliative and oncology care could improve QoL and other important aspects of patient...

Pembrolizumab Increases 24-Month PFS2 in PD-L1+ HNSCC
https://www.targetedonc.com/view/pembrolizumab-increases-24-month-pfs2-in-pd-l1-hnscc

May 29th, 2020 - Patients with PD-L1-positive relapsed/refractory head and neck squamous cell carcinoma (HNSCC) who were treated in the KEYNOTE-048 trial experienced and improvement in progression-free survival after subsequent therapy (PFS2) with pembrolizumab (Keytruda) compared with the EXTREME regimen. The PFS2 benefit was consistent in patients who received pembrolizumab alone and those who received added ...

Responses to Olaparib/Cediranib Combination in Ovarian Cancer Warrant Further Investigation
https://www.targetedonc.com/view/responses-to-olaparib-cediranib-combination-in-ovarian-cancer-warrant-further-investigation

May 28th, 2020 - Phase 3 trial results demonstrated comparable activity of cediranib and olaparib (Lynparza) with standard-of-care platinum-based chemotherapy in the treatment of recurrent platinum-sensitive ovarian cancer, despite missing the primary end point of progression-free survival (PFS) improvement. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific P...

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumab-doubles-24month-pfs2-in-pdl1-hnscc

May 29th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.

Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment
https://www.onclive.com/conference-coverage/asco-2020/cediranibolaparib-combo-yields-comparable-results-to-chemo-in-ovarian-cancer-treatment

May 28th, 2020 - A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
https://ascopost.com/news/june-2020/cediranibolaparib-vs-standard-of-care-chemotherapy-for-platinum-sensitive-ovarian-cancer/

Jun 1st, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...

Widespread Impact of COVID-19 on Cancer Research and Treatment
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200211/full/

May 29th, 2020 - There is no doubt that the COVID-19 pandemic has negatively affected cancer research and patient treatment worldwide. ASCO addressed this during the ASCO20 Virtual Scientific Program during the session, “Cancer Care in the Time of COVID: Assessing Impact and Future Directions.” The session began with an overview given by Norman E. Sharpless, MD, director of the National Cancer Institute (NCI). ...

Patients With HNSCC Experience Longer PFS After Combination Pembrolizumab and Chemotherapy, Subsequent Therapy
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200208/full/

May 29th, 2020 - Patients treated with pembrolizumab or pembrolizumab plus chemotherapy as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had longer progression-free survival (PFS) after the next line of therapy than patients first treated with the EXTREME regimen, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 6505).

Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma
https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/

May 31st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lung Cancer Oral Abstract Session at the ASCO20 Virtual Scientific Program (Abstract 9003). The trial evaluated the addition of durvalumab, an immune che...

Identification of antiviral drug candidates against SARS-CoV-2 from FDA -approved drugs
https://aac.asm.org/content/aac/early/2020/04/28/AAC.00819-20.full.pdf
Antimicrobial Agents and Chemotherapy;

Drug repositioning is the only feasible option to address the COVID-19 global challenge immediately.

ASCO Preview: Boosting Survival in Ovarian Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86486

May 13th, 2020 - Women with relapsed, platinum-sensitive ovarian cancer associated with BRCA mutations lived more than a year longer if they received olaparib (Lynparza) following chemotherapy, data from a randomized trial showed.

FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA

Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other malignancy.

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Practice Advisory: Cell-free DNA to Screen for Single-Gene Disorders
https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Cell-free-DNA-to-Screen-for-Single-Gene-Disorders

Feb 20th, 2019 - The continued innovation in cell-free technology combined with the desire for a maternal blood test to predict the risk for fetal genetic disorders during a pregnancy has broadened the application of cell-free DNA screening beyond aneuploidy to single-gene disorders. Examples of single-gene disorders include various skeletal dysplasias, sickle cell disease and cystic fibrosis. Although this tec...

Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study
http://ascopubs.org/doi/abs/10.1200/JCO.18.00822
Pui,C.,et al

Jan 17th, 2019 - We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. This retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and...

FDA grants priority review to Keytruda for first-line treatment of advanced head and neck cancer
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/%7Bf7be7f0c-f55a-4770-89bf-caf27f834e43%7D/fda-grants-priority-review-to-keytruda-for-first-line-treatment-of-advanced-head-and-neck-cancer

Feb 10th, 2019 - The FDA granted priority review to pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The designation applies to use of pembrolizumab (Keytruda, Merck) — an anti-PD-1 agent — as monotherapy or in combination with platinum and 5-FU chemotherapy.

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
https://meetinglibrary.asco.org/record/169433/abstract
Unno,M.,et al

Jan 17th, 2019 - Despite improvements of postoperative adjuvant therapy for resected pancreatic ductal adenocarcinoma (PDAC), its prognosis remains poor. A randomized controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S1 (NAC-GS) with upfront surgery (Up-S) for patients with PDAC planned resection. ASCO GI Symposium

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric...
https://meetinglibrary.asco.org/record/169297/abstract
Shah,M.,et al

Jan 16th, 2019 - Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. A phase I/Ib study of mFOLFOX6 + ADX revealed encouraging antitumor activity in patients (pts) with gastric or gastroesophageal junction (GEJ) adenocarcinoma (median first-line, progression-free survival [PFS] of 9.9 months)....